HomeInvestingEarningsLLY, MRK, PFE: Biopharma’s Back In 2024

LLY, MRK, PFE: Biopharma’s Back In 2024

Expect 2024 to be the year of gradual recovery for biopharmaceuticals, notes CFRA’s Sel Hardy. She and Jefferies’ Brian Tanquilut discuss health care trends to watch in 2024. Hardy mentions that oncology and diabetes will be the fastest growing therapy areas. Her top stock picks include Eli Lilly (LLY), Merck (MRK), and Pfizer (PFE). Tanquilut highlights that Jefferies continues to like HCA given the solid company fundamentals, reasonable valuation, and opportunity for earnings upside. Tune in to find out more about the stock market today.

Trading 360

13 Dec 2023

SHARE

ON AIR
2:00 am
Next Gen Investing
replay
12:00 am
Trading 360
REPLAY
1:00 am
Fast Market
REPLAY
ON AIR
2:00 am
Next Gen Investing
REPLAY
3:00 am
Market Overtime
REPLAY
3:30 am
Market Overtime
REPLAY
education
4:00 am
Your First Trade
REPLAY
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Inside the Mind of a Trader
REPLAY
education
5:30 am
Inside the Mind of a Trader
REPLAY
6:00 am
Gamma On
REPLAY
6:30 am
Gamma On
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Gamma On
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Gamma On
REPLAY
9:30 pm
Market Overtime
REPLAY
education
10:00 pm
Inside the Mind of a Trader
REPLAY
education
10:30 pm
Inside the Mind of a Trader
REPLAY
education
11:00 pm
Inside the Mind of a Trader
REPLAY
education
11:30 pm
Your First Trade
REPLAY

Get the Market Minute

Daily insights for every investor